Explores definitions of genetic tests and their implications for insurance in diverse regions, highlighting access issues.
Multi-cancer early detection (MCED) tests are increasingly popular. Are these tests "genetic," and if so, can insurers use them in the risk assessment process? This article reviews definitions of genetic tests. It then reviews the motivation for limiting insurers' access to genetic tests and examines the wording in the legislation in 3 countries and 1 US state. It then attempts to establish whether MECD results are included in the legislation.
No takes yet. Share an insight, caveat, or question.
Timothy J. Meagher (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: